Head-to-head · WeighScore
Modern Age vs Omada Health
The verdict
Modern Age takes it — 58.7/100 to 55.6/100.
Modern Age grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Modern Age is a longevity-focused health clinic that uses FDA-approved branded GLP-1 medication (semaglutide - Wegovy/Ozempic) within a structured Weight Loss Program.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Modern Age | Omada Health |
|---|---|---|
| WeighScore | 58.7/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #361 | #436 |
| Semaglutide | Not disclosed | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #361 · C
Strengths
- Uses FDA-approved branded GLP-1 medication (Wegovy/Ozempic), no compounding
- Comprehensive assessment with labs, at-home tests and clinician review
- Board-certified clinicians and structured 6-month program
- Longevity-oriented, whole-person approach beyond weight loss
Where it loses points
- Expensive: $500 assessment plus $500 program, with medication billed separately
- Branded GLP-1 can cost $900-1600/mo if not covered by insurance
- Only available in 16 states (specific states not listed publicly)
- Premium positioning makes it costlier than compounded-subscription rivals
Graded #436 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.